Drug updated on 11/13/2023

Dosage FormInjection (intravenous: 300 mg/10 mL)
Drug ClassCD20-directed cytolytic antibodies
Ongoing and Completed StudiesClinicalTrials.gov


  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
  • For the treatment of primary progressive MS in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Ocrevus (Ocrelizumab) Prescribing Information.2022Genentech USA, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative efficacy of therapies forrelapsing multiple sclerosis: a systematicreview and network meta-analysis.2023Journal of Comparative Effectiveness Research
A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis.2023International Immunopharmacology
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis.2023Neurological Sciences
Ocrelizumab for multiple sclerosis.2022Cochrane Database of Systematic Reviews
Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders.2022Frontiers in Immunology
Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis.2022Neurological Sciences
Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.2021Autoimmunity Reviews
Efficacy classification of modern therapies in multiple sclerosis. 2021Journal of Comparative Effectiveness Research
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. 2020Expert Opinion on Drug Safety
A systematic review and mixed treatment comparison of pharmaceutical Interventions for multiple sclerosis. 2020Neurology and Therapy
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. 2020Journal of Comparative Effectiveness Research
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. 2019Multiple Sclerosis and Related Disorders
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. 2019Journal of Neurology
Clinical review report: ocrelizumab (Ocrevus) - Primary progressive multiple sclerosis.2018CADTH
Ocrelizumab for treating relapsing–remitting multiple sclerosis. 2018NICE

Clinical Practice Guidelines